SEC Filing Summary: BioRestorative Therapies, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioRestorative Therapies, Inc. on October 7, 2019. The Company, an emerging growth company incorporated in Delaware, reported the entry into a material definitive agreement involving a debt financing transaction.
Key Financial Metrics and Transaction Details
The filing details a specific financing event rather than periodic financial performance metrics such as revenue or operating margins.
- Principal Amount: $850,000 convertible promissory note issued to Auctus Fund, LLC.
- Net Proceeds: $773,500 received by the Company.
- Interest Rate: 12% per annum.
- Maturity Date: April 7, 2020.
- Conversion Terms: Convertible at the option of the holder into common stock at 58% of the market price at the time of conversion.
- Warrant Issuance: A five-year warrant for 100,000 shares at an exercise price of $0.35 per share.
- Use of Proceeds: Prepayment of an existing convertible promissory note.
The filing text does not provide clear values for total revenue, net profit, operating cash flow, total debt, or liquidity ratios as of the reporting date.
Material Changes
The primary material change is the creation of a new direct financial obligation and the issuance of unregistered equity securities (warrants). The Company utilized the new financing to retire prior debt, altering its capital structure. No comparative period financial data is provided in this filing to assess changes in operational metrics.
Outlook, Risks, and Contingencies
Management Commentary: The Company relied on Section 4(a)(2) of the Securities Act of 1933 for the exemption from registration, asserting that the transaction did not involve a public offering and that the investor is accredited.
Risks and Contingencies:
- Dilution Risk: The conversion price of 58% of the market price and the warrant exercise price of $0.35 present significant potential for shareholder dilution if the stock price rises or if the note is converted.
- Liquidity Risk: The Company required new financing to prepay existing debt, indicating potential liquidity constraints.
- Debt Obligation: The Company has a fixed obligation to repay $850,000 plus interest by April 7, 2020, unless converted.
Investor Verification Checklist
- Verify the current market price of the common stock to assess the immediate dilution impact of the 58% conversion discount.
- Confirm the status of the prepayed convertible note to understand the net reduction in total debt.
- Review the full text of the Convertible Promissory Note (Exhibit 10.1) and Warrant (Exhibit 10.2) for specific adjustment mechanisms and default provisions.
- Check subsequent filings for updates on the Company's cash position and ability to service the debt at maturity in April 2020.